<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> is a multisystem disease that is characterized by <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and is associated with the dysfunction and failure of various organs </plain></SENT>
<SENT sid="1" pm="."><plain>The control of <z:hpo ids='HP_0011998'>postprandial hyperglycemia</z:hpo> is important in the prevention and intervention of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Fucoidan has several biological activities in vitro and in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>However, the effect of fucoidan on <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in non-diabetic and diabetic mice has not been investigated </plain></SENT>
<SENT sid="4" pm="."><plain>This study was undertaken to study the effects of different molecular weight forms (5 kilodalton (k), 5-30 k and crude) of fucoidan on oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance tests in non-diabetic mice and on food intake, <z:mp ids='MP_0005456'>weight gain</z:mp>, fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> and blood biochemistry of db/db mice </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with 200 mg/mL 5 k, 5-30 k and crude fucoidan substantially prevented <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> according to oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance tests in non-diabetic mice </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, fucoidan fractions significantly reduced blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels in diabetic mice </plain></SENT>
</text></document>